Published Date: 17 Feb 2023
BACKGROUND: NSCLC is the most common and important cause of cancer worldwide. Assessment: The patient...
Read Full NewsBritish lawmakers rejected on Friday a proposal to legalise assisted dying for terminally ill people, dealing a major setback to campaigners and bringing the latest effort...
In a global review, legalization was associated with increased cannabis use and related emergency department visits, with potential decreases in the use of alcohol and tobacco.
Researchers analyzed plasma samples collected from 313 patients with early breast cancer approximately 2 years after they had completed adjuvant chemotherapy.
Patients who respond to neoadjuvant immunochemotherapy may be able to undergo less extensive surgery, with high rates of disease control and organ preservation.
In patients with first- or second-line Philadelphia-positive B-cell acute lymphoblastic leukemia, favorable outcomes are observed with discontinuation of ponatinib.
For patients with early-stage, inoperable lung cancer, adding atezolizumab to standard radiotherapy boosts toxicity, not survival.
1.
Extended lymphadenectomy has no survival benefit in patients with muscle-invasive bladder cancer.
2.
Did U.S. Government Play a Role in Remote Tribe's Widespread Illness and Cancer?
3.
New CAR-T Drug Induces Durable Remissions in ALL, Published Data Show
4.
Preoperative MRI is useful for identifying additional disease in breast cancer patients with nodes positive.
5.
Key mechanism behind prostate cancer drug resistance reveals potential new treatment strategy
1.
The Importance of Having a Quick and Effective Heparin Antidote
2.
Pediatric Oncology at the Cutting Edge: From Early Diagnosis to Lifesaving Therapies
3.
Hepatocellular Carcinoma: Progress in Detection, Pathogenesis, and Treatment
4.
National Blood Health Promotion Strategies: Evidence-Based Approaches for Improved Outcomes
5.
Safety Monitoring of Complement Inhibitors in Hematologic Disorders
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part II
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII
3.
Understanding Iron Deficiency and Its Common Symptoms
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation